首页> 外文期刊>亚太热带生物医学杂志(英文版) >In vivo hypoglycemic investigation, antihyperglycemic and antihyperlipidemic potentials of Pereskia bleo Kunth. in normal and streptozotocin-induced diabetic rats
【24h】

In vivo hypoglycemic investigation, antihyperglycemic and antihyperlipidemic potentials of Pereskia bleo Kunth. in normal and streptozotocin-induced diabetic rats

机译:Pereskia bleo Kunth的体内降血糖研究,降血糖和降血脂的潜力。在正常和链脲佐菌素诱导的糖尿病大鼠中

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To elucidate the in vivo hypoglycemic capability, antihyperglycemic and antihyperlipidemic activities of Pereskia bleo (Kunth) leaves extracts and bioactive fraction. Methods: The various solvent extracts of Pereskia bleo were investigated for the hypoglycemic and antihyperglycemic activities using a relevant in vivo normal rat model and streptozotocin-induced diabetic rat model with glibenclamide and metformin utilized as positive controls. The effects of the most potent extract and its bioactive fraction on the insulin level, lipid profile and body weight of the diabetic rats were also analyzed. Results: All the extracts showed no hypoglycemic effect while petroleum ether, chloroform and aqueous extracts demonstrated significant (P<0.05) reduction in blood sugar level in the intraperitoneal glucose tolerance test. Aqueous extract and aqueous fraction significantly (P<0.05) reduced the blood glucose level in streptozotocin-induced diabetic rats as early as day 6 compared to the diabetic control as well as significantly restored the serum insulin of diabetic rats. Moreover, the aqueous extract and aqueous fraction disclosed a significant (P<0.05) reduction in total cholesterol, triglycerides, and low-density lipoprotein levels. An elevation in high-density lipoprotein as well as improved body weight loss of the diabetic rats were also observed. Conclusions: In summary, Pereskia bleo appears effective in the management of diabetes and correlated impairments arising from high blood sugar level. Further studies will possibly bring about the discovery of effective and secure plant derived antidiabetic drugs.
机译:目的:阐明Pereskia bleo(Kunth)叶提取物的体内降血糖能力,降血糖和降血脂活性以及生物活性成分。方法:使用相关的体内正常大鼠模型和链脲佐菌素诱导的糖尿病大鼠模型,以格列本脲和二甲双胍为阳性对照,研究了Pereskia bleo的各种溶剂提取物的降血糖和抗降血糖活性。还分析了最有效的提取物及其生物活性成分对糖尿病大鼠胰岛素水平,脂质分布和体重的影响。结果:在腹膜内葡萄糖耐量试验中,所有提取物均未显示降血糖作用,而石油醚,氯仿和水提取物均显示血糖水平显着降低(P <0.05)。与糖尿病对照组相比,最早在第6天,水提取物和水部分显着降低(P <0.05)链脲佐菌素诱导的糖尿病大鼠的血糖水平,并显着恢复糖尿病大鼠的血清胰岛素。此外,水提取物和水部分显示总胆固醇,甘油三酸酯和低密度脂蛋白水平显着(P <0.05)降低。还观察到高密度脂蛋白的升高以及糖尿病大鼠体重的改善。结论:总之,Pereskia bleo似乎对糖尿病的治疗有效,并伴有因高血糖引起的损害。进一步的研究可能会导致发现有效和安全的植物来源的抗糖尿病药物。

著录项

  • 来源
  • 作者单位

    School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia;

    School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia;

    School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia;

    School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia;

    School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia;

    School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号